Recent developments include Q2 2026 earnings surpassing estimates, Q1 2026 earnings highlights, and ongoing challenges related to sales execution and macroeconomic conditions.

• Definitive Healthcare reported Q2 2026 earnings surpassing estimates with revenue of $55.2 million and net loss of $5.4 million [N1].
• Q1 2026 earnings call highlighted operational updates and financial results [N4].
• The company topped Q1 2026 earnings estimates and provided a detailed earnings transcript [N5][N6].
• Analysts noted expectations of a decline in earnings prior to Q2 2026 results [N3].
• The company has faced sales execution challenges and lower renewal rates impacting results in 2025 and into 2026 [S1].

The company has demonstrated the ability to expand its platform through acquisitions such as Populi and Carevoyance, enhancing its data and analytics offerings. Its subscription-based SaaS model provides recurring revenue streams from a diverse customer base across multiple healthcare segments. Recent restructuring efforts aim to improve operating margins and profitability. The company maintains a strong liquidity position with a current ratio of 1.86 and cash ratio of 1.42 as of June 30, 2026. Signs of improving macroeconomic conditions and customer demand were noted late in 2025, which could support stabilization of revenue growth and customer retention.

Definitive Healthcare has faced sustained declines in market capitalization leading to significant goodwill impairment charges over the past three years. Sales execution challenges and lower renewal rates have impacted financial results in 2025 and into 2026. The company received a Nasdaq notice for bid price non-compliance, posing a risk of delisting that could affect liquidity and capital raising. Macroeconomic headwinds have increased customer churn, especially among smaller customers and in Life Sciences. Ongoing litigation related to acquisition earn-outs introduces uncertainty. Executive transitions and restructuring may disrupt operations and execution.

Definitive Healthcare's moat is based on its comprehensive and specialized healthcare commercial intelligence platform delivered via SaaS, which integrates multiple data sources and analytics tailored to the complex healthcare ecosystem. Its broad customer base across Life Sciences, Provider, and Diversified markets, along with a large identified addressable market, supports its competitive position. The company's ongoing platform enhancements, acquisitions to expand data and analytics capabilities, and subscription-based recurring revenue model contribute to customer retention and switching costs. However, the company faces risks from market fluctuations, customer churn, and competitive pressures in the healthcare data and analytics space.

• Nasdaq Listing Compliance Risk: The company received a notice in June 2026 for its Class A common stock bid price closing below $1.00 for 30 consecutive business days, with a compliance deadline of December 15, 2026. Failure to regain compliance could lead to delisting, adversely affecting stock liquidity, price, and capital raising ability.
• Litigation Related to Acquisition Earn-Outs: The company is engaged in litigation with former Populi equity holders over contingent consideration payments. Management disputes additional payment claims but the ultimate outcome is uncertain and could impact financial condition.
• Macroeconomic and Market Conditions: Challenging macroeconomic conditions since 2022 have affected customer spending and increased churn, particularly among smaller customers and in the Life Sciences market, impacting revenue growth and renewal rates.
• Goodwill Impairment Risk: Sustained declines in market capitalization have led to significant goodwill impairment charges in recent years. Continued declines or adverse market conditions could result in further impairments affecting reported earnings.
• Sales Execution and Customer Retention: Changes in go-to-market strategy and restructuring have caused disruptions in sales efforts, impacting new customer acquisition and upsell. Lower renewal rates have affected financial results.

• Definitive Healthcare Corp. is a provider of healthcare commercial intelligence delivered through a SaaS platform.
• The company serves approximately 2,330 customers as of December 31, 2025, across three end markets: Life Sciences, Provider, and Diversified.
• Revenue is generated substantially all from subscription fees.
• The company was founded in 2011 by Executive Chairman Jason Krantz.
• The total addressable market is estimated at over $11 billion, with a serviceable addressable market of approximately $7 billion and more than 100,000 potential customers identified.
• Recent acquisitions include Populi in July 2023 for $54.1 million and Carevoyance in January 2024 for $13.7 million.
• The company has experienced goodwill impairment charges in 2023, 2024, and 2025 due to declines in market capitalization.
• A restructuring plan in 2024 reduced workforce by approximately 150 people to reduce costs and improve margins.
• The company has faced sales execution challenges and lower renewal rates impacting results in 2025 and into 2026.
• Executive leadership changes occurred in 2024 and 2025, including CFO transition and elimination of COO position.
• Macroeconomic conditions since 2022 have affected customer spending and increased churn, especially among smaller customers and in Life Sciences.
• As of June 30, 2026, the company reported cash and equivalents of $170.9 million, short-term investments of $12.7 million, current assets of $240.1 million, current liabilities of $129.1 million, a current ratio of 1.86, and a cash ratio of 1.42.
• For the quarter ended June 30, 2026, revenue was $55.2 million and net loss was $5.4 million, with basic and diluted EPS of -$0.05 per share.
• The company received a Nasdaq notice in June 2026 for bid price below $1.00 per share, with a compliance period until December 15, 2026.
• The company leases its corporate headquarters in Framingham, Massachusetts, and has offices in Sweden and India.
• The audit committee oversees cybersecurity risk management with quarterly reporting and involvement of executive leadership.
• The company is engaged in litigation related to contingent consideration from the Populi acquisition but believes no additional amounts are payable.
• The company has no current plans to pay dividends on Class A common stock.
• Recent news includes Q2 2026 earnings surpassing estimates and Q1 2026 earnings highlights and transcripts.
• The company trades on Nasdaq Global Select Market under ticker DH.